- Home
- WINT vs KZIA Comparison
WINT vs KZIA Comparison
Compare WINT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- KZIA
- Stock Information
- Founded
- WINT 1992
- KZIA 1994
- Country
- WINT United States
- KZIA Australia
- Employees
- WINT N/A
- KZIA N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- WINT Health Care
- KZIA Health Care
- Exchange
- WINT Nasdaq
- KZIA Nasdaq
- Market Cap
- WINT 996.6K
- KZIA 860.8K
- IPO Year
- WINT 1995
- KZIA 1999
- Fundamental
- Price
- WINT $1.21
- KZIA $3.64
- Analyst Decision
- WINT Hold
- KZIA Strong Buy
- Analyst Count
- WINT 1
- KZIA 2
- Target Price
- WINT $350.00
- KZIA $57.50
- AVG Volume (30 Days)
- WINT 347.1K
- KZIA 30.1K
- Earning Date
- WINT 05-06-2025
- KZIA 05-02-2025
- Dividend Yield
- WINT N/A
- KZIA N/A
- EPS Growth
- WINT N/A
- KZIA N/A
- EPS
- WINT N/A
- KZIA N/A
- Revenue
- WINT N/A
- KZIA $1,655,324.00
- Revenue This Year
- WINT N/A
- KZIA N/A
- Revenue Next Year
- WINT N/A
- KZIA N/A
- P/E Ratio
- WINT N/A
- KZIA N/A
- Revenue Growth
- WINT N/A
- KZIA 248000.00
- 52 Week Low
- WINT $1.01
- KZIA $2.86
- 52 Week High
- WINT $737.50
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- WINT 35.07
- KZIA 44.45
- Support Level
- WINT $1.01
- KZIA $2.86
- Resistance Level
- WINT $1.19
- KZIA $3.77
- Average True Range (ATR)
- WINT 0.14
- KZIA 0.50
- MACD
- WINT 0.12
- KZIA 0.05
- Stochastic Oscillator
- WINT 41.67
- KZIA 60.00
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.